Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

mTOR / PI3-Kinase

Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.

Bayard R. Huck, Andreas Machl, Erik Wilker, Hui Tian, Sakeena Syed, Jing Lin, Jianguo Ma, Anderson Clark, Roseann Waterhouse, Remiguisz Kaleta, Alina Micu, Lynne Soughley, Long Li, Karin Groll, Sonja Kroesser, Frank Beier, Ursula Hering, Marc Lecomte, Katrin Wichert, Mauro D'Antonio and Paolo Di Eugenio
Bayard R. Huck
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Machl
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Wilker
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Tian
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sakeena Syed
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Lin
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianguo Ma
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anderson Clark
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roseann Waterhouse
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Remiguisz Kaleta
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Micu
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynne Soughley
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Long Li
1EMD Serono, Inc., Billerica, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Groll
2Merck Serono, KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonja Kroesser
2Merck Serono, KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Beier
2Merck Serono, KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ursula Hering
2Merck Serono, KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lecomte
2Merck Serono, KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin Wichert
2Merck Serono, KGaA, Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauro D'Antonio
3Merck Serono RBM, Ivrea, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Di Eugenio
4Merck Serono, Inc., Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-13-A162 Published November 2013
  • Article
  • Info & Metrics
Loading

Abstract

The PI3K pathway is involved in the regulation of cell growth, proliferation, metabolism and other functions. Aberrant signaling (PTEN loss of function, PIK3CA mutation, Akt amplification, etc.) from the PI3K pathway is observed in >50% of all tumors. Clinical evidence suggests that inhibiting the PI3K pathway is beneficial for the treatment of solid tumors and tumors of the hematopoietic system. Inhibition of p70S6K via rapalogs has been shown to block a negative feedback loop, thereby leading to the activation of Akt. The activation of this Akt feedback loop has been suggested to potentially compromise the clinical efficacy of selective mTORC1 inhibitors such as temsirolimus and everolimus. Dual p70S6K/Akt inhibition may promote improved pathway inhibition and also block the negative consequences of Akt activation through the negative feedback loop.

MSC2363318A is a highly kinase-selective, potent, adenosine triphosphate (ATP) competitive inhibitor of p70S6K, Akt1, and Akt3. In a cellular context, inhibition of p70S6K leads to potent inhibition of ribosomal protein S6 phosphorylation, while inhibition of Akt activity blocks the negative effects of a compensatory feedback loop. In addition, MSC2363318A exhibits potent anti-proliferative activity against many solid tumor cell lines in vitro, especially those with PI3K pathway genomic alterations. Further, MSC2363318A can also cross the blood-brain barrier, a unique characteristic that would allow for treating not only primary malignancies that are driven by PI3K pathway genomic alterations, but also indications with a high incidence of CNS metastases and primary malignancies of the central nervous system.

Oral treatment of mice with MSC2363318A resulted in significant inhibition of tumor growth in several subcutaneous human cancer xenograft models representing breast, pancreatic, glioblastoma and ovarian cancers. Of note, a breast cancer model possessing a PTEN loss of function showed tumor regression upon treatment with MSC2363318A. In addition, MSC2363318A exhibited increased exposure in tumors as compared to plasma, resulting in sustained inhibition of S6K phosphorylation for up to 24 hours. Key preclinical activities are being completed and first in human clinical studies are scheduled to be initiated in 2013.

Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A162.

Citation Format: Bayard R. Huck, Andreas Machl, Erik Wilker, Hui Tian, Sakeena Syed, Jing Lin, Jianguo Ma, Anderson Clark, Roseann Waterhouse, Remiguisz Kaleta, Alina Micu, Lynne Soughley, Long Li, Karin Groll, Sonja Kroesser, Frank Beier, Ursula Hering, Marc Lecomte, Katrin Wichert, Mauro D'Antonio, Paolo Di Eugenio. Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A162.

  • Copyright © November 2013, American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 12 (11 Supplement)
November 2013
Volume 12, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.
Bayard R. Huck, Andreas Machl, Erik Wilker, Hui Tian, Sakeena Syed, Jing Lin, Jianguo Ma, Anderson Clark, Roseann Waterhouse, Remiguisz Kaleta, Alina Micu, Lynne Soughley, Long Li, Karin Groll, Sonja Kroesser, Frank Beier, Ursula Hering, Marc Lecomte, Katrin Wichert, Mauro D'Antonio and Paolo Di Eugenio
Mol Cancer Ther November 1 2013 (12) (11 Supplement) A162; DOI: 10.1158/1535-7163.TARG-13-A162

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.
Bayard R. Huck, Andreas Machl, Erik Wilker, Hui Tian, Sakeena Syed, Jing Lin, Jianguo Ma, Anderson Clark, Roseann Waterhouse, Remiguisz Kaleta, Alina Micu, Lynne Soughley, Long Li, Karin Groll, Sonja Kroesser, Frank Beier, Ursula Hering, Marc Lecomte, Katrin Wichert, Mauro D'Antonio and Paolo Di Eugenio
Mol Cancer Ther November 1 2013 (12) (11 Supplement) A162; DOI: 10.1158/1535-7163.TARG-13-A162
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

mTOR / PI3-Kinase

  • Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas
  • Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations
  • Abstract B107: Metabolic reprogramming enhances the efficacy of mTOR inhibition in colorectal cancer
Show more mTOR / PI3-Kinase

mTOR / PI3-Kinase: Poster Presentations - Proffered Abstracts

  • Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas
  • Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations
  • Abstract B107: Metabolic reprogramming enhances the efficacy of mTOR inhibition in colorectal cancer
Show more mTOR / PI3-Kinase: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement